Randomized, Double-blind, Double-masked, Parallel-group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Latest Information Update: 19 Nov 2024
At a glance
- Drugs N 0728 (Primary) ; Solifenacin/tamsulosin
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Acronyms BENIPRO
- Sponsors Eurofarma
Most Recent Events
- 15 Nov 2024 Planned number of patients changed from 614 to 816.
- 16 Aug 2024 New trial record